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RUNNING TITLE: Molecular analysis of methicillin resistance factor MecR2 
Background: PBP2a-based methicillin resistance in S. aureus 
is regulated by the MecR2. 
Results: The structure of MecR2 shows a dimeric multi-
domain ROK-family protein, which non-specifically binds 
oligonucleotides but not ligands. 
Conclusion: MecR2 represents an evolution within ROK 
proteins to give rise to a protein-binding anti-repressor. 
 
Significance: The present results pave the way for the design 
of new antimicrobials. 
SUMMARY 
Methicillin resistance in Staphylococcus aureus is 
elicited by the MecI-MecR1-MecA axis encoded by the 
mec locus. Recently, MecR2 was also identified as the 
third regulator of mec through binding of the methicillin 
repressor, MecI. Here we show that plasmid-encoded full-
length MecR2 restores resistance in a sensitive S. aureus 
mecR2 deletion mutant of the resistant strain N315. The 
crystal structure of MecR2 reveals an N-terminal DNA-
binding domain (NDD), an intermediate scaffold domain 
(ISD), and a C-terminal dimerization domain (CDD) that 
contributes to oligomerization. The protein shows 
structural similarity to ROK (from repressors, open-
reading frames and kinases) family proteins, which bind 
DNA and/or sugar molecules. We found that functional 
cell-based assays of three point mutants affecting residues 
participating in sugar binding in ROK proteins had no 
effect on the resistance phenotype. By contrast, MecR2 
bound short double-stranded DNA oligonucleotides non-
specifically and a deletion mutant affecting the NDD 
showed a certain effect on activity, thus contributing to 
resistance less than the wild-type protein. Similarly, a 
deletion mutant, in which a flexible segment of ISD had 
been replaced by four glycines, significantly reduced 
MecR2 function, thus indicating that this domain may 
likewise be required for activity. Taken together, these 
results provide the structural basis for the activity of 
methicillin anti-repressor, MecR2, which would sequester 
MecI away from its cognate promoter region and facilitate 
its degradation.  
Staphylococcus aureus is the most prevalent human 
infectious agent associated with nosocomial and community 
infections. It has an extraordinary capacity to become 
resistant to antibiotics: it was the first bacterial pathogen 
reported to have become insensitive to penicillin (1-4). 
Among the distinct strains is methicillin-resistant S. aureus 
(MRSA), which currently refers to strains that are generally 
resistant to β-lactam antibiotics (BLAs; penicillins and 
cephalosporins). Some strains are also resistant to other 
chemotherapeutics such as aminoglycosides, glycopeptides, 
macrolides, lincosamides, and fluoroquinolones (3,5-8). 
MRSA is characterized by its ability to thrive in the presence 
of BLAs due to the biosynthesis of a penicillin-binding 
protein with low susceptibility to BLAs, termed PBP2a, 
PBP2’ or MecA. The latter is encoded by the gene mecA, 
which is contained in a transducible mobile element, 
staphylococcal chromosomal cassette mec (SCCmec) (9-11). 
SCCmec also includes two genes, mecI and mecR1, which 
encode a transcriptional DNA-binding repressor, MecI, and 
an integral-membrane zinc-dependent sensor/signal 
transducer metalloproteinase, MecR1, respectively (12,13). 
This system is homologous to the blaI-blaR1-blaZ signal 
transduction system that triggers synthesis of a β-lactamase 
(BlaZ) in both MRSA and methicillin-susceptible S. aureus, 
as well as in Bacillus licheniformis (14-16). The currently 
accepted working model hypothesis for these systems predicts 
that MecI/BlaI constitutively represses its own biosynthesis 
and that of MecR1/BlaR1 and MecA/BlaZ through binding to 
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the mec/bla promoter (10,13,17). Once MecR1/BlaR1 detects 
the presence of BLAs through its extracellular sensor domain 
(18-22), a signal is transmitted across the membrane to the 
intracellular zinc-dependent metalloproteinase domain, which 
becomes activated through proteolytic cleavage (23-25). This 
yields functional MecR1/BlaR1, which, in turn, would—
directly or indirectly—cause cleavage of MecI/BlaI (26,27). 
This cleavage would render the dimeric repressor inactive and 
release it from its DNA binding site. A similar effect of 
inhibitor inactivation, which was not based, however, on a 
proteolytic pathway but on the intracellular presence of a 
short dipeptidic peptidoglycan fragment induced by BLA 
stress, has been recently described for B. licheniformis (28). 
Finally, release of transcriptional repression would elicit 
biosynthesis of MecA/BlaZ. 
However, some lines of evidence are not explained by 
this ternary model. Firstly, the reported cleavage sites of 
MecR1/BlaR1 and MecI/BlaI are not compatible with a single 
proteolytic substrate specificity (29). Secondly, the structure 
of MecI and BlaI in complexes with target DNA revealed that 
the repressor cleavage site is found within an α-helix and is 
not surface accessible (29-32), as would be required for 
proper proteolytic processing. Thirdly, highly-resistant 
MRSA strains did not show significant variation in the 
phenotypic expression of resistance when wild-type MecI was 
overexpressed in trans (33). Lastly, the presence of functional 
MecR1-MecI did not correlate with the level of BLA 
resistance in a representative collection of epidemic MRSA 
strains (33). These and other findings led several authors to 
postulate the existence of a further regulatory element, 
MecR2/BlaR2, although no candidate molecules were 
suggested (4,10,17,18,31,32,34-38).  
Most recently, comparative genomic sequence analysis 
revealed that, in some clinical MRSA strains, a putative gene 
is found upstream of mecA, which is co-transcribed with mecI 
and mecR1(34). Its transcript could be detected by reverse-
transcriptase PCR of cultures induced with oxacillin—a 
methicillin analogue that has replaced the latter in clinical 
use—from a set of prototype clinical MRSA strains, 
paralleling mecA induction. Furthermore, in the presence of 
fully functional MecR1 and MecI, this gene was essential for 
the optimal expression of BLA resistance. Finally, in vitro 
and in vivo assays showed that the encoded protein acted as 
an anti-repressor by disrupting MecI binding to the mecA 
promoter and fostering its MecR1-independent proteolytic 
inactivation (34). Collectively, these findings indicated that 
the long sought-for gene encoding MecR2/BlaR2 had been 
found, and so it was termed mecR2 (34).  
In order to shed light on the structural determinants of 
folding and function of MecR2, we developed an efficient 
protocol to produce and purify large quantities of the 
functional wild-type protein. Furthermore, we assayed activity 
of MecR2 in cell-based assays and in vitro, and determined its 
X-ray crystal structure. We report here the molecular 
determinants of its function, which were further validated by 
mutational studies. 
 
EXPERIMENTAL PROCEDURES 
Recombinant overexpression and purification — The 
mecR2 gene was amplified from genomic DNA from S. 
aureus strain HU25 (M1-A376, see GenBank AF422694, 
protein sequence identical to UniProt entry Q99XE2) by PCR 
and cloned into expression vector pCri8a between NcoI and 
XhoI restriction sites, giving rise to plasmid pCri8::mecR2 
(for strains and plasmids used in this study, see Table 1). This 
construct added an N-terminal His6-tag and a tobacco-etch 
virus (TEV) protease cleavage site; the N-terminus of the 
mature protein was, thus, preceded by a twenty-residue 
segment (M-21GSSHHHHHHSSGENLYFQGP-1; amino-acid 
one-letter-code; superscript numbers depict protein residue 
numbering with negative numbers referring to extra N-
terminal residues preceding the mature N-terminus, which is 
M1 according to Q99XE2). A mutant, in which segment T150-
I160 had been replaced by four glycine residues (termed 
MecR2-T150-I160→GGGG), was amplified from the 
pST181::spac::mecR2 recombinant plasmid by PCR and 
cloned into expression vector pCri8a at the NcoI and XhoI 
restriction sites. Expression vectors were transformed into 
Escherichia coli BL21 DE3 cells and 1 liter cultures of 
transformed bacteria were induced for protein expression with 
0.1mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) at 
18ºC for 24h when the optical density at λ=600nm (OD600) 
reached 0.6. Cultures were subsequently centrifuged at 
7,000×g (4ºC, 20min) and pellets resuspended in 70ml ice-
cold buffer A (20mM Tris·HCl, 0.5M sodium chloride, 
pH8.0). Cells were lysed with a cell disruptor (Constant Cell 
Disruption Systems Ltd.) operated at 1.35KBar, and the lysate 
was subsequently centrifuged at 75,600×g in an Avanti J-25 
centrifuge with a JA-25.50 rotor (4ºC, 20min). The soluble 
fraction containing His6-TEV-MecR2 was applied onto a His-
trap FF crude column (GE Healthcare) attached to an ÄKTA 
Purifier UPC-10 FPLC system previously equilibrated with 
buffer A. The protein was eluted with an imidazole gradient 
(0 to 0.5M imidazole in buffer A) and fractions containing the 
protein were subjected to a final size-exclusion 
chromatography step in a Superdex 75 16/60 column (GE 
Healthcare), previously equilibrated with 20mM Tris·HCl, 
0.2M sodium chloride, pH7.4. Protein purity was assessed by 
10%-tricine SDS-PAGE. TEV protease digestion of the N-
terminal His6-tag was assayed under different conditions but 
yields were not satisfactory. As such, crystallization trials 
were performed using tagged MecR2 (hereafter wild-type 
MecR2). The selenomethionine variant of MecR2 was 
obtained in the same manner, except that 30min before 
induction the cells were added to 500ml of medium lacking 
methionine and containing 25mg of selenomethionine 
(Sigma-Aldrich) instead. 
Circular dichroism experiments – The CD spectra of 
wild-type MecR2 and MecR2-T150-I160→GGGG were 
recorded with a JASCO J-815 CD spectrometer operated with 
the following parameters: response 1s; scan speed 50nm/min; 
data acquisition interval 0.1nm; accumulations 3; and 
bandwidth 1nm. Quartz cuvettes for far-UV (190–250nm) 
with path lengths of 1 mm were used. Samples contained 0.2 
mg/mL protein in 10mM sodium phosphate; 40mM sodium 
chloride, pH7.0. The CD spectrum of cuvette and buffer alone 
was subtracted from the protein solution spectra. 
MecR2 DNA-binding assays in vitro — Recombinant 
wild-type MecR2 was assayed for DNA-binding capacity by 
electrophoretic mobility shift analysis. The 25-bp 
oligonucleotides encompassing the Z-dyad sequence of the 
bla promoter sequence with an additional 1-bp overhang on 
either end (C/G), which had been employed in structure-
function studies with MecI (15,29,30) (termed here MR2-
 
Arêde et al.                                                                                                                                                3 
  
EMSA1 and 2, see Table 2), were purchased from Sigma and 
annealed as described to yield 200nmol of double-stranded 
(ds) DNA in buffer 20mM Tris·HCl, 0.1M sodium chloride, 
pH7.4. Purified MecR2 (100µM and 200µM) in buffer 20mM 
Tris·HCl, 0.2M sodium chloride, pH7.4 was mixed with DNA 
solution at 0.5:1, 1:1, 2:1, and 4:1 protein:dsDNA molar ratios 
and analyzed in a band-shift assay in an 18.5% PAGE gel 
using annealed oligonucleotides as negative control. The same 
experiment was repeated with 25-bp nucleotides of same 
nucleotide composition but scrambled sequence (MR2-
EMSA3 and 4).  
Site-directed mutagenesis of MecR2 — MecR2 mutant 
variants were obtained as previously described (39,40). 
Briefly, a round of two independent PCR reactions was 
performed on pCri8::mecR2 with two complementary 
mutagenic primers and the two flanking mecR2 primers 
generating two intermediate PCR products with overlapping 
terminals (for primers and nucleotides, see Table 2). For the 
deletion mutant lacking segment S55-K62 (protein MecR2-Δ 
S55-K62), primer pairs MR2-3D F1/MR2-SDM2 and MR2-3D 
R1/MR2-SDM1 were used; for deletion mutant MecR2-T150-
I160→GGGG, primers MR2-SDM4 and MR2-SDM3 were 
used; and for point mutants E228A (MecR2-E228→A), 
N178A+E179A (MecR2-N178E179→AA), and E248A (MecR2-
E248→A), the respective primers were MR2-SDM10 and 
MR2-SDM9, MR2-SDM14 and MR2-SDM15, and MR2-
SDM12 and MR2-SDM11. Both intermediate PCR products 
were then diluted 50 times and mixed to form the DNA 
template of the second PCR, using primers spanning the entire 
mecR2 gene (MR2–3D F1/R1). All PCR reactions were 
performed with the Phusion High-Fidelity DNA Polymerase 
(New England Biolabs). 
Cell-based activity of recombinant MecR2 — In order 
to assess the activity of recombinant wild-type MecR2 
expressed from vector pCri8a::mecR2 and the aforementioned 
mutants generated by site-directed mutagenesis, the full 
respective inserts were cloned into a S. aureus expression 
vector containing the Pspac IPTG-inducible promoter 
(pSPT181::spac). Briefly, using flanking primers MR2-3D 
F1/R1, the insert sequence was amplified using the Phusion 
High-Fidelity DNA Polymerase (New England Biolabs) and, 
after digestion with XmaI (New England Biolabs), inserted 
into the XmaI linearized pSPT181::spac plasmid using the 
Rapid DNA Dephos & Ligation kit (Roche), according to the 
manufacturer’s recommendations. Ligation reactions were 
transformed into E. coli DH5α cells. Recombinant plasmid 
integrity was confirmed by restriction analysis and the correct 
insert orientation was confirmed by PCR using primer pairs 
spacF1/MR2-RT2 and spacR1/MR2-RT1. Insert sequences 
were also confirmed by DNA sequencing at STAB Vida 
(www.stabvida.com). After stabilization in E. coli, the 
recombinant plasmid was electroporated into S. aureus 
restriction-deficient strain RN4220 and finally transduced by 
the 80α phage to the knock-out mecR2 mutant strain N315 
(N315::ΔmecR2), as previously described (41,42). The ability 
of the recombinant wild-type and mutant MecR2 expressed in 
trans to complement the N315::ΔmecR2 oxacillin-resistance 
phenotype was then evaluated, as previously described (34). 
Crosslinking experiments — Recombinant MecR2 
(45.0KDa) was mixed with MecI (14.8KDa)—produced as 
previously described (30)—at a molar ration of 1:2.8 in 50µl 
of 100mM HEPES, pH9.0. Paraformaldehyde was added as 
cross-linking agent at 0.1% (v/v) and the mixture was 
incubated at room temperature. The reaction was stopped at 
distinct time points by adding 10µl 5x Laemmli buffer with β-
mercaptoethanol. Samples were analyzed by 10%-tricine 
SDS-PAGE gels stained with Coomassie-blue. Control 
experiments were performed with both purified proteins alone 
under the same experimental conditions. 
Western blotting analysis – The cross-linking reaction 
was performed as aforementioned and three different time 
points (0, 10, 30min) were analyzed in 15% Tris-Glycine 
SDS-PAGE. After electrophoresis, the proteins were 
transferred to 0.45-µm nitrocellulose membranes (Trans-Blot, 
Bio-Rad), which were blocked at room temperature for 1h 
with 20mL of blocking solution (137mM sodium chloride; 
2.7mM potassium chloride; 4.3mM disodium hydrogen 
phosphate; 1.47mM potassium dihydrogen phosphate; 0.05% 
Tween-20) with 6% low-fat milk. MecI and MecR2 were 
detected by immunoblot analysis using custom polyclonal 
antibodies (from Eurogentec) at dilution 1:1000 and a 
secondary antibody (goat anti-rabbit IgG (H+L) peroxidase 
conjugated antibody, from Pierce) at dilution 1:50,000 in 10% 
blocking solution. The immune complexes were detected 
using an enhanced chemiluminescence system (SuperSignal 
West Pico Chemiluminescent; Pierce) according to the 
manufacturer's instruction. Membranes were exposed to 
hyperfilm ECL films (GE Healthcare). 
Crystallization and structure analysis – Crystallization 
assays were performed by the sitting-drop vapor diffusion 
method. Reservoir solutions were prepared by a Tecan robot 
and 100nL crystallization drops were dispensed on 96x2-well 
MRC plates (Innovadyne) by a Cartesian nanodrop robot 
(Genomic Solutions) at the High-Throughput Crystallography 
Platform at Barcelona Science Park for initial screenings both 
at 20 and 4ºC in Bruker steady-temperature crystal farms and 
using initial protein concentrations of 5.4 and 2.7mg/ml. 
Preliminary crystallization hits were improved and best 
conditions were scaled up to the microliter range in 24-well 
Cryschem crystallization dishes (Hampton Research). 
Crystals suitable for structure analysis were obtained at 
5.4mg/ml protein concentration in 20 mM Tris·HCl, 200 mM 
sodium chloride, pH7.4 by using 0.2M sodium chloride, 20% 
PEG 1000, 0.1M potassium dihydrogen phosphate/ disodium 
hydrogen phosphate, pH6.2 as reservoir solution. Crystals 
were cryo-protected with reservoir solution supplemented 
with 30% glycerol. Crystallization conditions for the 
selenomethione-derivatized protein were similar to the native 
ones. Complete diffraction datasets were collected from 
liquid-N2 flash-cryo-cooled crystals at 100K (provided by an 
Oxford Cryosystems 700 series cryostream) at beam lines 
ID23-1 on an ADSC Quantum Q315r CCD detector and ID29 
on a Dectris PILATUS 6M pixel detector, respectively, of the 
European Synchrotron Radiation Facility (ESRF, Grenoble, 
France) within the “Block Allocation Group Barcelona.” 
Crystals were orthorhombic, with two molecules per 
asymmetric unit. Diffraction data were integrated, scaled, 
merged, and reduced with programs XDS (43) and SCALA 
(44) within the CCP4 suite of programs (45) (see Table 3).  
The structure of MecR2 was solved by a combination 
of multiple-wavelength anomalous diffraction with 
SHELXE/D (46) and fragment search and density 
modification with ARCIMBOLDO (47) by using two native 
datasets and two datasets from a selenomethionine-derivatized 
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crystal collected at the selenium absorption peak and the 
inflection point as determined by a previous XANES scan 
(Table 3). The resulting electron density map enabled 
straightforward tracing of the entire polypeptide chain on a 
Silicon Graphics Octane2 workstation with program TURBO-
Frodo (48). Subsequent crystallographic refinement with 
BUSTER/TNT (49), which included Translation Libration 
Screw-motion refinement and non-crystallographic symmetry 
restraints, alternated with manual model building until 
completion of the model. The latter comprised residues M1 to 
A376 according to UniProt entry Q99XE2 plus an N-terminal 
proline resulting from the cloning strategy (termed P-1; see 
above) of molecule A, and D3 to A376 of molecule B. Three 
loop segments were disordered and were thus omitted from 
the final model: E52-S58 and L152-E158 of molecule A, and G51-
P63 of molecule B. In addition, one phosphate anion, four 
potassium cations, six glycerol molecules, and 278 solvent 
molecules were tentatively assigned (Table 3). 
Miscellaneous – Figures were prepared with SETOR 
(50), CHIMERA (51), and TURBO-Frodo. Structure 
similarities were determined with DALI (52). Experimental 
model validation was performed with MOLPROBITY (53) 
and WHATIF (54). Close contacts (<4Å) and interaction 
surfaces (taken as half of the surface area buried at the 
complex interface) were calculated with CNS (55), and 
interface shape complementarity was computed with SC (56) 
within CCP4 (45). In all cases, a probe radius of 1.4Å was 
used. Inter-domain flexibility was ascertained with 
HINGEPROT employing standard settings ((57); see 
http://bioinfo3d.cs.tau.ac.il/HingeProt). The final coordinates 
are available from the Protein Data Bank (PDB) at 
www.pdb.org (access code 4IJA). 
 
RESULTS AND DISCUSSION 
 
Recombinant overexpression and purification of 
MecR2 — Previously, the effects of MecR2 on oxacillin-
resistance had been studied with a short variant present in the 
S. aureus prototype strain N315 lacking the first 87 residues 
of the full-length protein (34). Preliminary recombinant 
overexpression assays in E. coli revealed that this short 
variant was unstable and, as such, an efficient recombinant 
overexpression system was developed for full-length MecR2 
of S. aureus strain HU25 (GenBank AF422694) containing an 
additional 20-residue N-terminal tag for purification 
(45.0KDa; hereafter wild-type MecR2) by means of 
expression vector pCri8::mecR2. The protein was folded 
correctly, eluted as a dimer (Fig. 2c), and proved suitable for 
structural and functional studies. 
Cell-based activity of recombinant MecR2 —In order 
to assess the activity of full-length wild-type MecR2 
(including the tag), the insert of vector pCri8::mecR2 was 
transferred into S. aureus expression vector pSPT181::spac 
(containing the IPTG-inducible Pspac promoter) to give 
recombinant plasmid pSPT::spac-mecR2-3D. This plasmid 
was then transduced into the S. aureus strain N315 mecR2 
deletion mutant (N315::ΔmecR2) and its ability to restore the 
oxacillin-resistance phenotype of parental strain N315 was 
evaluated. As illustrated in Fig. 1, the phenotype of N315 was 
fully restored in the presence of the inducer (IPTG), 
demonstrating that the present full-length wild-type MecR2 
variant is biologically active.  
MecR2 binds MecI in cross-linking experiments — 
Previous studies had suggested a direct interaction between 
MecR2 and MecI in a bacterial two-hybrid system and in 
electrophoretic shift assays of the binding of MecI to the 
mecA promoter in the presence of MecR2 (34). In this study, 
we sought to evaluate the binding of recombinant MecI and 
wild-type MecR2 proteins in vitro. Control cross-linking 
experiments with each protein alone indicated concentration-
dependent dimerization of both proteins (data not shown), in 
accordance with the dimeric behaviour of each of both 
proteins in solution (see above for MecR2 and (30) for MecI). 
When performing SDS-PAGE of cross-linking reactions of a 
mixture of MecI and MecR2 with paraformaldehyde, a time-
dependent transition leading to a band migrating as ~120KDa 
was observed (Fig. 2a). Western blotting analysis with 
polyclonal antibodies against both proteins at three different 
time points of the cross-linking reaction confirmed in the 
~120-KDa band (Fig. 2a, black frames) the presence of both 
MecI and MecR2 (Fig. 2b), which is consistent with a MecR2 
dimer (2x45.0KDa) binding to a MecI dimer (2x14.8KDa). 
Overall structure of MecR2 — The crystal structure of 
MecR2 was determined by a combination of multiple-
wavelength anomalous diffraction and ab initio approaches, 
and two molecules are present in the asymmetric unit of the 
crystal, monomers A and B (see Table 3 for crystallographic 
data). The monomer structure reveals an elongated shape of 
roughly 45x60x80Å that is subdivided into three domains: an 
N-terminal DNA-binding domain (NDD), an intermediate 
scaffold domain (ISD), and a C-terminal dimerization domain 
(CDD)(Fig. 3a; the orientation of the left panel is hereafter 
taken as a reference). NDD (residues P-1/D3-H70) starts at the 
front surface, close to the top of the molecule, and enters a 
small αβ domain. It consists of three α-helices (α1-α3) 
followed by a β-ribbon (β1β2) whose tip—the loop 
connecting β1 and β2 (Lβ1β2)—is disordered (Fig. 3a,b). 
These elements conform to the architecture of a winged helix-
turn-helix domain as observed in DNA-binding transcriptional 
repressors, which generally show disordered β-ribbon tips 
when not bound to operator DNA (58). In the latter, α1 and α2 
contribute to creating a scaffold for correct positioning of 
helix α3. This is the recognition helix that penetrates the 
major groove of double-stranded DNA, as found in e.g. the 
DNA-binding domains (DBDs) of MecI and BlaI (29-32).  
After strand β2, the polypeptide chain enters ISD 
(residues L71-N193 + S346-A376), which contains a central 
twisted five-stranded β-sheet (β3-β6 plus β9) that is parallel 
for all but one of its strands and shows connectivity -1,-
1,+3x,+1x (Fig. 3b,c). On its right, the sheet accommodates 
two helices (α4 and α5) and a short β-hairpin (β7β8), which is 
inserted between β6 and α5 and is folded back towards the 
sheet (Fig. 3a,b); on its left, two perpendicular helices (α6 and 
α12) are found. In monomer A, segment L152-E158 within 
Lβ8α5 on the front surface of the molecule was disordered 
(Fig. 3a,b). Inserted between the latter helices is the CDD 
(residues L194-T345), which starts with a five-stranded β-sheet 
(β10- β12 plus β15-β16) that is equivalent to the one found in 
ISD, both in connectivity and topology (Fig. 3b,c). On its 
bottom side, this sheet is decorated with helices inserted 
between β12 and β15 (α7-α9) and between β15 and β16 (α10 
and α11). In addition, a long β-ribbon (β13β14) is inserted 
 
Arêde et al.                                                                                                                                                5 
  
between β12 and α7; it contributes to oligomerization (see 
below). The overall architecture of ISD and CDD is such that 
the two respective β-sheets trap helices α6 and α12 in between 
so that a pseudo-twofold axis is generated which matches one 
sheet plus its helix with the other sheet-helix pair (Fig. 3b). 
Thus, α6 could be formally assigned to either ISD or CDD. 
The interface between these two domains contributes to an 
apparent ligand-binding cleft (Figs. 3b and 4a). It is framed by 
Lβ6β7 and β7 at its top; β10, Lβ10β11, β11 plus Lβ12β13 and 
Lβ14α7 at its bottom; Lβ9α6 and α6 at its back; residue Y82 of 
Lβ3β4 on its right; and R200 of β10 and E177 of β9 on its left 
(Fig. 4a). The cleft accommodates two (potential) potassium 
cations and a (tentative) phosphate anion in monomer A; in 
monomer B only one cation-binding site is found, which is 
created by atoms N181 Oδ1, A210 O, and A226 O, all 2.6-2.9Å 
apart from the metal. A further three (monomer B) and four 
(monomer A) solvent molecules 3.0-3.6Å apart from the 
metal complete the ligand sphere of this site. The rightmost 
potassium of monomer A is much more loosely bound, with 
just two protein atoms at <3.5Å, N314 O and S203 Oγ. Finally, 
the phosphate anion of monomer A is bound by N178 Nδ2, 
H140 Nδ1, E179 Oε1 and a solvent molecule (Fig. 4a). 
Oligomeric state of MecR2 — MecR2 eluted as a 
dimer in calibrated size-exclusion chromatography and a 
dimer was also found to bind a MecI dimer in cross-linking 
experiments (see above). Consistent with this, the two 
molecules found in the crystal asymmetric unit give rise to a 
dimer with a large interaction surface (1,465Å2; ~8% of the 
total surface of a monomer) with complementarity (0.72) that 
is in the range reported for protein oligomers and 
protein/protein inhibitor interfaces (0.70-0.76; (56)). This 
interaction includes 83 contacts (<4Å), among them roughly 
symmetric hydrophobic contacts between nine residues of 
either monomer, and 34 hydrogen bonds and polar 
interactions. Altogether, these findings point to biological 
relevance for the dimeric arrangement. Protein segments 
involved in dimerization are provided by each CDD: Lα6β10, 
Lβ11β12, the second half of α9 and Lα9β15, and β-ribbon 
β13β14. The two monomers are not completely equivalent, 
and this gives rise to an rmsd value upon superposition of 
0.97Å for 353 Cα-atoms deviating less than 3Å of out 361 
common residues. Analysis of inter-domain flexibility based 
on the elastic network model revealed potential hinge motions 
at the two domain junctions of each monomer, which increase 
on going from the CDDs to the NDDs (Fig. 4c).  
Structural similarities — Sequence similarity 
searches suggested that MecR2 groups with the ROK family 
of proteins (from repressors, open-reading frames, and 
kinases), which includes transcriptional repressors and sugar 
kinases (59-61). One archetypal ROK protein is xylose 
transcriptional repressor (XylR), which regulates xylose 
utilization as a carbon source in bacteria (62-66). However, 
there is no structural data on XylR available. E. coli protein 
Mlc is the only functionally and structurally characterized 
ROK-family protein with DNA-repressor function (60,67). 
Mlc is a dimeric/tetrameric transcriptional repressor that 
controls the utilization of glucose in E. coli (68). It shows 
overall fold similarity and quaternary arrangement with 
MecR2 and is likewise subdivided into three domains 
equivalent to NDD, ISD, and CDD. In addition, two 
unpublished structures corresponding to proteins of unknown 
function from Thermotoga maritima (PDB code 2HOE) and 
Vibrio cholerae (PDB 1Z05), deposited with the PDB by 
structural genomics consortia, also displayed high structural 
similarity scores with MecR2. These are the only three-
domain ROK proteins structurally reported, which form part 
of a large group of mostly two-domain (ISD+CDD) ROK 
proteins, generally dimeric or tetrameric sugar kinases that 
bind and phosphorylate glucides (59-61,69). 
MecR2 has a non-functional ligand-binding cleft — 
As for MecR2, Mlc has a ligand-binding cleft that sits at the 
interface between ISD and CDD. It further has an adjacent 
regulatory zinc-binding site, which is required for repressor 
activity (60) and is provided by the segment topologically 
equivalent to the protruding β-ribbon β13β14 in MecR2. In 
contrast to the latter, however, this segment is folded back 
towards the body of the molecule in Mlc, in a similar fashion 
to that in ROK glucokinase from E. coli (70) and 
glucomannokinase from Arthrobacter sp. (71), where it 
contributes to shaping the floor of a sugar-binding cleft. This 
segment encompasses a widely conserved consensus sequence 
among ROK proteins, CXCGXXGCXE (60,69), which 
contains three zinc-binding cysteine residues. A similar site is 
also found in Bacillus subtilis fructokinase YdhR (72), an 
undescribed putative glucokinase from Enterococcus faecalis 
(PDB 2QM1), an undescribed putative regulatory protein 
from Salmonella typhimurium (PDB 2AP1), and the 
aforementioned protein from V. cholerae, so that ROK family 
members containing this consensus sequence share a 
conserved metal-binding site. By contrast, MecR2 lacks these 
cysteine residues, and its chain trace is completely different, 
giving rise to an extended β-ribbon that engages in 
dimerization (see above). This β-ribbon is similar in the 
aforementioned protein from T. maritima, although in this 
case the ribbon is four residues shorter than that in MecR2. 
Only the last glutamate of the consensus sequence is found in 
the latter two proteins—E248 in MecR2—and it contributes to 
the hypothetical ligand-binding cleft (see above).  
Another ROK-signature motif is found in several 
ROK proteins comprising the C-terminal residues EXGH, 
about ten residues upstream of the previous consensus 
sequence (see Fig. 4 in (69)). The histidine—missing in 
MecR2—is engaged in zinc binding in Mlc and the V. 
cholerae protein, while the glutamate—equivalent to E228 in 
MecR2—is engaged in sugar binding in E. coli glucokinase 
and Arthrobacter sp. glucomannokinase, together with the 
conserved residues at positions equivalent to E248, N178, and 
E179 in MecR2. The latter two residues are engaged in 
phosphate anion binding (see above). Although these residues 
are likewise conserved in Mlc, this protein does not bind 
glucose, i.e. its regulation does not depend on allosteric-
changes induced by sugar binding (73): inactivation is exerted 
through recruitment by the glucose transporter protein 
EIICBGlc of the phosphotransferase system (74-76). By 
contrast, XylR binds xylose, glucose, and glucose-6-
phosphate in vitro (66), i.e. it is a three-domain transcriptional 
repressor with a functional regulatory sugar-binding cleft. 
Overall, these findings indicate that ROK proteins include 
members that bind sugars such as the sugar kinases and XylR 
but also some that do not such as Mlc. Accordingly, we set 
out to assess if MecR2 has a functional sugar-binding ligand-
binding site despite lacking the zinc-binding site, and three 
mutants affecting participating residues (MecR2-
N178E179→AA, MecR2-E228→A, and MecR2-E248→A) were 
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constructed and assayed for their functional roles in the mec 
locus. These studies revealed that the mutants showed anti-
repressor activity in cell-based assays that was 
indistinguishable from the wild-type protein (Fig. 1). We 
therefore conclude that ligand binding is not required for 
function in MecR2, i.e. that is has a non-functional ligand-
binding cleft. 
MecR2 has non-specific DNA-binding capacity — 
Three-domain ROK transcriptional repressors such as Mlc 
and XylR possess N-terminal DBDs that engage in DNA-
operator binding and, thus, in the regulation of the 
transcription of the respective effector genes (60,65). MecR2 
NDD likewise conforms to the structural determinants of such 
a DBD (see above). The reported structures of Mlc, T. 
maritima and V. cholerae are DNA-unbound, and they display 
the two recognition helices of a dimer in a relative spatial 
arrangement that is not adequate for binding to two successive 
turns of the major groove of double-stranded (ds) DNA 
(60,67). This is consistent with the finding that structural 
flexibility—which allows for major structural 
rearrangement—of Mlc was identified as essential for DNA-
binding activity and regulatory function (67).  
We set out to assess the DNA-binding capacity of 
MecR2 in an electrophoretic mobility shift assay in the 
presence of a 25-base pair (bp) dsDNA encompassing the Z-
dyad sequence of the bla promoter sequence (see MR2-
EMSA1 and 2 in Table 2), which had been used for structural 
and functional studies of MecI (29,30). We found that MecR2 
strongly bound and completely retarded this DNA at a 
protein:dsDNA ratio of 4:1 (Fig. 5, left). Similar effects were 
observed on another 25-bp dsDNA of scrambled sequence 
(see MR2-EMSA 3 and 4 in Table 2; Fig. 5, right). These 
results indicate strong but unspecific DNA binding in vitro. 
To assess the potential biological importance of this function, 
a deletion mutant was constructed, MecR2-ΔS55-K62, in which 
seven residues of Lβ1β2 within the winged-helix NDD had 
been deleted. This variant showed significantly diminished 
anti-repressor activity when compared with the wild-type 
protein (Fig. 1). We conclude that MecR2 possesses a 
functional DBD that may be required for exerting oxacillin 
resistance. 
ISD may be relevant for function — In the search for 
biologically-relevant regions of the structure of MecR2, we 
noticed that the flexible segment contained within Lβ8α5 of 
ISD was located on the surface of one of the two monomers 
within the dimer (see above and Fig. 4b). We constructed a 
mutant, in which an eleven-residue stretch was replaced by 
four glycines (MecR2-T150-I160→GGGG) to maintain the 
overall structure of the domain, and assayed its cell-based 
activity (Fig. 1). Similarly to MecR2-ΔS55-K62, this variant 
was not capable of restoring the oxacillin-resistance 
phenotype in the presence of inducer.  
To verify that this effect was not due to an unfolded   
protein variant, MecR2-T150-I160→GGGG was recombinantly 
overexpressed under the same conditions as wild-type 
MecR2. Both proteins evinced comparable elution profiles in 
calibrated size-exclusion chromatography, which revealed 
that both proteins were well folded and dimeric (Fig. 2c). In 
addition, circular dichroism experiments showed 
indistinguishable spectra for both protein variants, which 
likewise correspond to properly folded proteins (Fig. 2d). 
Accordingly, the phenotype observed for the mutant is 
actually due to the missing ISD fragment and we conclude 
that this region may be implicated in biological activity. 
Functional implications of MecR2 — The similarity 
of MecR2 with ROK-family bacterial sugar kinases and 
transcriptional repressors, both in the overall monomeric 
structures and the general dimeric quaternary arrangements 
have evolutionary and functional implications. Accordingly, 
XylR would represent the first step in evolution from an 
ancient two-domain ROK sugar-binding kinase—putatively 
evolved from a common ancestral hexokinase (69,77)—
refurbished to produce a three-domain DNA-binding 
transcriptional repressor through N-terminal fusion with a 
winged helix-turn-helix DBD. XylR still binds and is 
allosterically regulated by sugar. Mlc would represent the 
next step—as already anticipated in (60)—to a three-domain 
DNA-binding transcriptional repressor that does not bind 
sugar and is not regulated by binding to an inducer or by 
proteolytic cleavage but through sequestration by a glucose 
transporter, i.e. through a protein-protein interaction (67,76). 
Finally, MecR2 would represent a last step in the evolutionary 
process, in which a three-domain ligand-independent Mlc-like 
repressor would have kept an unspecific DNA-binding ability 
putatively required for biological function as an anti-
repressor. In addition, the dimeric protein would have 
developed a region within its ISD that potentially would 
likewise be required for antibiotic resistance. This anti-
repressor activity would entail binding and sequestering away 
from its cognate promoter a dimeric transcriptional repressor, 
MecI. Finally, MecI sequestering would suppress its repressor 
activity of the mec locus by promoting its proteolytic 
cleavage, presumably by native proteinases, and enhancing 
the signal transduction mediated by the cognate integral-
membrane sensor-transducer, MecR1. This, in turn, would 
trigger the methicillin-resistance response. 
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FIGURE LEGENDS  
Figure 1. Biological activity of wild-type and mutant MecR2 variants. The genes encoding wild-type full-length 
MecR2 (WT), as well as point and replacement mutants of the protein, were cloned into the S. aureus expression vector 
pSPT181::spac under the control of the IPTG-inducible Pspac promoter. The biological activity of the MecR2 variants was 
then evaluated by the inhibition halos produced by transformed S. aureus strains on oxacillin disks (containing 1 mg/mL of 
oxacillin), thus testing the complementation of the phenotype of the mecR2 null-mutant in prototype strain N315 
(N315::ΔmecR2). Top panel, resistant N315 strain (left) and susceptible N315::ΔmecR2 strain (right). Panels two to seven 
depict the effect of distinct MecR2 variants after induction with IPTG (left dishes) and without induction (right dishes): WT, 
MecR2-T150-I160→GGGG, MecR2-∆S55-K62, and point mutants MecR2-N178E179→AA, MecR2-E228→A, and MecR2-
E248→A. Variants MecR2-T150-I160→GGGG and MecR2-∆S55-K62 (framed) cannot reconstitute the resistant phenotype while 
the three latter point mutants can, i.e. they are functionally not relevant. 
Figure 2. In vitro studies of MecR2 and MecI proteins. (a) SDS-PAGE analysis of the time-dependent transition 
due to the action of paraformaldehyde from a mixture of purified MecI and MecR2 (14.8 and 45.0KDa, respectively) to 
MecR2-MecI heterotetramers. Due to the excess of MecI over MecR2 in the reaction mixture (2.8:1 molar ratio), MecR2 
progresses directly from the monomer to the heterotetrameric complex. In contrast, MecI proceeds from a monomer over a 
homodimer to the heterotetramer. (b) Western-blot analysis of three different time points of the reaction shown in (a) (0, 10, 
30min), confirming the presence of both MecI and MecR2 in the ~120-KDa heterotetrameric-complex bands (framed in (a)). 
(c) Elution profile of recombinant wild-type MecR2 (blue curve) and MecR2-T150-I160→GGGG mutant (red curve) proteins 
on a calibrated Superdex 75 size-exclusion chromatography column operated at 0.5mL/min using 20mM Tris·HCl, 0.2M 
sodium chloride, pH 7.4 as buffer. Cytochrome C (13.08mL;12KDa) was used as an internal marker for reference. 9.60mL 
elution volume correspond to ~90KDa. (d) Far-UV CD spectra of wild-type MecR2 (green curve) and MecR2-T150-
I160→GGGG (red curve) proteins in the native state in solution.  
Figure 3. Molecular structure of MecR2. (a) Ribbon-type plot of MecR2 in three orthogonal views depicting the 
NDD (cyan helices and blue strands), ISD (yellow helices and orange strands), and CDD (pink helices and magenta strands). 
The bound tentative potassium and phosphate ions (monomer A) are depicted as green and orange/red spheres, respectively. 
The flanking residues of the disordered regions within NDD and ISD are indicated by black and gray arrows, respectively. 
(b) Topology scheme of MecR2 showing the regular secondary structure elements of MecR2 with their labels and delimiting 
amino-acid positions. A twofold axis relating the β-sheets of ISD and CDD is depicted in discontinuous trace. The position 
of the ligand-binding cleft is further indicated. (c) Cartoon depicting the topology of the main building elements of ISD and 
CDD, the five-stranded β-sheet and its three flanking helices. Each structural element carries the labels as found in the two 
domains. The arrows hallmark insertion points of distinct secondary structure elements within each domain: 1 for ISD and 
2 for CDD.  
Figure 4. Ligand-binding cleft and quaternary structure of MecR2. (a) Detail of the apparent ligand-binding cleft of 
MecR2 monomer A in stereo. Selected residues, the phosphate anion and the two potassium cations are labeled. (b) MecR2 
dimer made up of monomer A (right; similar orientation to Fig.3a, left) and monomer B (left). The three domains are 
depicted in cyan/blue (NDD), salmon/orange (ISD), and purple/magenta (CDD). Potassium and phosphate ions are shown as 
green and orange/red spheres, respectively. The flanking residues of the flexible region within Lβ8α5 of ISD are indicated by 
black arrows. (c) Same as (b) showing the result of the analysis of inter-domain flexibility based on the elastic network 
model. 
Figure 5. Electrophoretic mobility shift assays with MecR2. Electrophoretic mobility shift assays with a 25-bp 
dsDNA encompassing the recognition sequence of MecI/BlaI within the blaZ promoter (left) and a 25-bp dsDNA with the 
same nucleotide composition but scrambled sequence (right). In each case, the left lanes depict controls with DNA alone and 
lanes 2 to 5 show the effect of increasing amounts of MecR2 protein (protein:dsDNA ratios of 0.5:1, 1:1, 2:1, and 4:1). 
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Table 1 — Strains and plasmids 
 
 
Strain/Plasmid 
 
Relevant characteristics 
 
Source 
Strains   
E. coli DH5α Recipient strain for recombinant plasmids Stratagene 
E. coli Bl21 (DE3)  Recipient strain for expression vector pCri8a Novagene 
BL21 + pCri8a::mecR2 E. coli BL21 (DE3) overexpressing mecR2 with an N-terminal His6-tag 
and a TEV protease cleavage site 
This study 
S. aureus RN4220 Restriction-deficient derivative of reference strain NCTC8325-4  R. Novick 
S. aureus N315 Prototype MRSA strain, heterogeneous Oxar, wild-type mecR1-mecI, 
mecR2 positive (short variant ΔN87), β-lactamase positive, clone ST5-II 
K. Hiramatsu 
 
S. aureus HU25 Homogeneous Oxar, wild-type mecR1, truncated mecI, mecR2 positive 
(full-length protein), β-lactamase positive, clone ST239-III 
(33) 
N315::ΔmecR2 N315 mecR2 deletion backcross, β-lactamase positive (34) 
N315::ΔmecR2 + 
   pSPT::spac-mecR2 
N315::ΔmecR2 expressing mecR2 from strain N315 in trans from the 
inducible Pspac promoter 
(34) 
   
Plasmids   
pCri8a   pET30 (Invitrogen) derivative for recombinant overexpression 
containing His6-GST-Tev fragment, Kanr 
(78) 
pSPT181::spac pSPT181 with 1.6 kb EcoR1-BamH1 fragment containing the IPTG 
inducible Pspac promoter and the transcriptional repressor LacI from 
pDH88, Apr, Tcr 
(34) 
pCri8a::mecR2 pCri8a expression vector with mecR2 gene from strain HU25 This study 
pSPT181::spac-mecR2 
3D (wild-type) 
pSPT181 vector containing the mecR2 gene from strain HU25 with an 
N-terminal His6-tag and a TEV protease cleavage site from 
pCri8a::mecR2 
This study 
pCri8a::mecR2 T150-I160→GGGG pCri82 expression vector containing the mecR2 mutant  variant T150-
I160→GGGG 
This study 
pSPT181::spac-mecR2  
ΔS55-K623 pSPT181 vector containing the mecR2 mutant variant ΔS55-K623 
 
This study 
pSPT181::spac-mecR2  
T150-I160→GGGG  pSPT181 vector containing the mecR2 mutant variant T
150-I160→GGGG  
 
This study 
pSPT181::spac-mecR2  
N178A, E179A pSPT181 vector containing the mecR2 mutant variant N
178A, E179A 
 
This study 
pSPT181::spac-mecR2 
E228A pSPT181 vector containing the mecR2 mutant variant E
228A 
 
This study 
pSPT181::spac-mecR2 
E248A pSPT181 vector containing the mecR2 mutant variant E
248A 
 
This study 
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Table 2 — Primers and oligonucleotides 
Name Sequence (5’ → 3’) * 
MR2-3D  F1 TATACCCGGGAAGGAGATATACCATGGGCA 
MR2-3D  R1 TATACCCGGGGCTATTATGCTTTTATATCTA 
Spac F1 GAAGATTTATTTGAGGTAGC 
Spac R1 TTATGGCTTGAACAATCACG 
MR2-RT1 AATGAAGCGAATCTTTCAGC 
MR2-RT2 AATTGCTAATGTACCACCTAGC 
MR2-SDM1 ATGAGGTTGGTGAGGGTGATAAACCTATTCTTCTGAAGGT 
MR2-SDM2 ACCTTCAGAAGAATAGGTTTATCACCCTCACCAACCTCAT 
MR2-SDM3 TGGATAATGAGCAGCATGTGGGTGGAGGTGGAATTTCAATTCCTAAGAA 
MR2-SDM4 TTCTTAGCAATTGAAATTCCACCTCCACCCACATGGTGCTCATTATCCA 
MR2-SDM9 ATGGGGAAGCGGGTGCAATTGGAAAAACACT 
MR2-SDM10 AGTGTTTTTCCAATTGCACCCGCTTCCCCAT 
MR2-SDM11 TCTTTCATAAGATTGCAGATATTTTTTCACA 
MR2-SDM12 TGTGAAAAAATATCTGCAATCTTATGAAAGA 
MR2-SDM13 CCAGTCGTAGTTGAAGCTGCAGCGAATCTTTCAGC 
MR2-SDM14 
MR2-EMSA1 
MR2-EMSA2 
MR2-EMSA3 
MR2-EMSA4 
GCTGAAAGATTGGCTGCAGCTTCAACTACGACTCC 
CAAAATTACAACTGTAATATCGGAG 
GCTCCGATATTACAGTTGTAATTTT 
CAACGGCGAAAATTCGCCAGTATAG 
GCTATACTGGCGAATTTTCGCCGTT 
* Restriction sites are underlined. 
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Table 3 — Crystallographic data 
Dataset  native 1 native 2 selenomethionine selenomethionine 
    absorption peak inflection point 
 
 
 
 
Cell constants (P212121; a, b, c, in Å) Cell constants (P212121; a,b,c in Å) 66.47, 73.22, 157.38 67.39, 73.14, 157.22 66.62, 73.25, 157.82 66.62, 73.25, 157.82 
Wavelength (Å) 0.97626 0.97919 0.97881 0.97908 
No. of measurements / unique reflections 402,549  /  45,488 356,882  /  39,911 213,853 / 34,902 154,830 / 24,460 
Resolution range (Å) (outermost shell) a 49.2 – 2.10 (2.21 – 2.10) 49.6 – 2.20 (2.32 – 2.20) 49.3 – 2.30 (2.42 – 2.30) 49.3 – 2.57 (2.75 – 2.57) 
Completeness (%) 99.6 (98.7)  99.1 (95.0)  99.5 (97.2) 99.9 (100.0) 
Rmerge b,c 0.087 (0.716)  0.104 (0.420) 0.054 (0.454) 0.089 (0.708) 
Rr.i.m. (= Rmeas) b,c / Rp.i.m. b,c 0.092 (0.777) / 0.030 (0.299)  0.110 (0.465) / 0.035 (0.194) 0.065 (0.568) / 0.035 (0.336) 0.106 (0.843) / 0.057 (0.451) 
Average intensity (<[<I> / σ(<I>)]>) 19.8 (2.7)  17.0 (3.6) 22.9 (3.1) 19.8 (2.6) 
B-Factor (Wilson) (Å2) / Average multiplicity 32.4  /  8.8 (6.4)  27.4  /  8.9 (5.2) 45.7  /  6.1 (4.7) 55.8  /  6.3 (6.4) 
Overall anomalous completeness (%) / multiplicity - - 98.3 / 3.2 99.4 / 3.3 
Resolution range used for refinement (Å) 49.2 – 2.10 
No. of reflections used (among these, test set) 45,433 (762)  
Crystallographic Rfactor (free Rfactor) c 0.190 (0.229)  
No. of protein atoms / solvent molecules / 5,813  /  278 / 
     ligands / ions 6 (CH2OH)2CHOH / 4 K+, 1 PO43- 
Rmsd from target values  
      bonds (Å)  /  angles (°) 0.010  /  1.04 
Average B-factors for protein atoms (Å2) 49.2 
Main-chain conformational angle analysis 
d 
      Residues in favored regions/outliers/all residues 
 
 705 / 0 / 714 
a
  Values in parentheses refer to the outermost resolution shell.
 b
  Friedel mates were treated separately during processing of selenomethionine-derivative data. 
c  For definitions, see Table 1 in (79).  
d
  According to MOLPROBITY (53). 
 





